{"id":"gan-lee-insulin-glargine-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog engineered with amino acid substitutions to provide a prolonged, peakless duration of action (up to 24 hours). It binds to the insulin receptor on muscle, adipose, and liver cells, facilitating glucose uptake and glycogen synthesis while inhibiting gluconeogenesis and lipolysis. This basal insulin replacement therapy is used to maintain fasting and between-meal glucose control in diabetes.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:40.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03371082","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (1) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":576},{"nctId":"NCT03371108","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (2) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT04236895","phase":"PHASE1","title":"PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2018-07-10","conditions":"Diabetes Mellitus, Type 1","enrollment":114},{"nctId":"NCT02506647","phase":"PHASE1","title":"PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2015-12","conditions":"Diabetes Mellitus, Type 1","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gan & Lee Insulin Glargine Injection","genericName":"Gan & Lee Insulin Glargine Injection","companyName":"Gan and Lee Pharmaceuticals, USA","companyId":"gan-and-lee-pharmaceuticals-usa","modality":"Biologic","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}